Algeria Noureddine Issad, general manager of Dar Al Dawa Algeria & Medi Pharma International unveils his ambitions to establish Dar Al Dawa as a major player in the Algerian market through local production of previously untapped product areas and discusses the new position of generics in the Algerian health industry. …
Spain Ana Fernández of Théa Spain discusses the strategic importance of the Spanish affiliate – the group’s oldest, current trends in Spanish ophthalmology, and what differentiates Théa – as a family-run mid-sized company – from its competitors. Having taken on your first country manager position in January 2018, what are…
Spain Spanish stakeholders have been trailblazing the concept of the “liquid hospital”, which envisions the virtual and physical expansion of healthcare provision beyond the parameters of the traditional centralized hospital structure. The aim is to leverage connectivity, telemedicine, the Internet of Things (IoT) along with social media to co-opt patients, families…
Medtech Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. He calls for healthcare to be given a new prescription. But, will the private sector write it? The UK’s National Health Service has crippling sustainability challenges. With many firms in the midst of or preparing for annual strategic planning sessions, it feels appropriate…
Hong Kong George Kwan, managing director of Hoya Lens, one of the first contact lens manufacturers in Hong Kong, introduces recent new innovation introduced to the market, public sector collaboration, and future strategy. George, could you start by introducing Hoya Lens Hong Kong to our international audience? Hoya Lens Hong Kong…
Algeria Nawel Baba Hamed, general director of Pierre Fabre Algeria, outlines the French company’s product portfolio in Algeria, its dermatological expertise, and the growing significance of its oncology segment. Could you introduce our readers to Pierre Fabre and its footprint in Algeria? Pierre Fabre is the second-largest dermo-cosmetic laboratory in…
BIOTECH This week the NHS becomes the first in the world to routinely offer access to breakthrough genomic medicine. Today (1st October 2018) marks a huge stride in ‘precision medicine’ in the UK as the NHS begins to offer gene therapies tailored to individual patients. Hospitals across England have connected to specialist…
Pfizer Pfizer today announced that Dr. Albert Bourla its Chief Operating Officer (COO) will succeed Ian Read as CEO effective January 1, 2019. Ian Read will transition from his current role as Chairman and CEO to Executive Chairman of Pfizer’s Board of Directors. “It’s been an honor to serve as Pfizer’s…
Opioids Today the USA finds itself in the midst of an opioid crisis, claiming 40,000 American lives every year – a comparable death toll to the HIV epidemic at its peak. Aside from the devastating human cost, it imposes a staggering annual economic burden of $504 billion US dollars, around three…
M&A It has been a robust first half in 2018 within the life sciences sector for mergers and acquisition (M&A) and investment activities. Deal-tracking sources demonstrate M&A values witnessed meaningful increases in Q2 2018, with deal volumes in the quarter reminiscent of 2016 and 2017 levels [1]. I and others [234] continue…
regulation The stakes are high, and the outcome is uncertain in one of the largest Pharma M&A deals ever. Takeda’s proposed acquisition of Shire seems to have it all: The combined entity becoming one of the largest global Pharma groups, enabling Takeda to become a truly global operation and allowing Shire’s…
Turkey Prof. Dr. Sabahattin Aydın, Rector of Medipol University, chairman of the Executive Council of TUSAP Healthcare Platform, former executive board member of the World Health Organization (WHO), former deputy undersecretary (2003-2010) at the Ministry of Health of Turkey, and one of the most respected healthcare leaders in Turkey, provides insights…
See our Cookie Privacy Policy Here